Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Prince, H Miles, Prof, Kim, Youn H, Prof, Horwitz, Steven M, MD, Dummer, Reinhard, Prof, Scarisbrick, Julia, MD, Quaglino, Pietro, Prof, Zinzani, Pier Luigi, Prof, Wolter, Pascal, MD, Sanches, Jose A, PhD, Ortiz-Romero, Pablo L, Prof, Akilov, Oleg E, MD, Geskin, Larisa, MD, Trotman, Judith, MD, Taylor, Kerry, MBBS, Dalle, Stephane, Prof, Weichenthal, Michael, Prof, Walewski, Jan, Prof, Fisher, David, MD, Dréno, Brigitte, Prof, Stadler, Rudolf, Prof, Feldman, Tatyana, MD, Kuzel, Timothy M, Prof, Wang, Yinghui, MS, Palanca-Wessels, Maria Corinna, MD, Zagadailov, Erin, PharmD, Trepicchio, William L, PhD, Zhang, Wenwen, PhD, Lin, Hui-Min, PhD, Liu, Yi, PhD, Huebner, Dirk, MD, Little, Meredith, MPH, Whittaker, Sean, Prof, Duvic, Madeleine, Prof
Published in The Lancet (British edition) (05.08.2017)
Published in The Lancet (British edition) (05.08.2017)
Get full text
Journal Article
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
Dréno, Brigitte, Prof, Kunstfeld, Rainer, Prof, Hauschild, Axel, Prof, Fosko, Scott, Prof, Zloty, David, MD, Labeille, Bruno, MD, Grob, Jean-Jacques, Prof, Puig, Susana, MD, Gilberg, Frank, PhD, Bergström, Daniel, PhD, Page, Damian R, PhD, Rogers, Gary, MD, Schadendorf, Dirk, Prof
Published in The lancet oncology (01.03.2017)
Published in The lancet oncology (01.03.2017)
Get full text
Journal Article
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Basset-Seguin, Nicole, Prof, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Kunstfeld, Rainer, Prof, Dréno, Brigitte, Prof, Mortier, Laurent, Prof, Ascierto, Paolo A, Prof, Licitra, Lisa, MD, Dutriaux, Caroline, MD, Thomas, Luc, Prof, Jouary, Thomas, MD, Meyer, Nicolas, MD, Guillot, Bernard, Prof, Dummer, Reinhard, Prof, Fife, Kate, MD, Ernst, D Scott, Prof, Williams, Sarah, MSc, Fittipaldo, Alberto, MD, Xynos, Ioannis, MD, Hansson, Johan, Prof
Published in The lancet oncology (01.06.2015)
Published in The lancet oncology (01.06.2015)
Get full text
Journal Article
Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Ascierto, Paolo A, MD, McArthur, Grant A, Prof, Dréno, Brigitte, Prof, Atkinson, Victoria, MD, Liszkay, Gabrielle, MD, Di Giacomo, Anna Maria, MD, Mandalà, Mario, MD, Demidov, Lev, MD, Stroyakovskiy, Daniil, MD, Thomas, Luc, Prof, de la Cruz-Merino, Luis, MD, Dutriaux, Caroline, MD, Garbe, Claus, Prof, Yan, Yibing, PhD, Wongchenko, Matthew, BS, Chang, Ilsung, PhD, Hsu, Jessie J, PhD, Koralek, Daniel O, PhD, Rooney, Isabelle, MBChB, Ribas, Antoni, Prof, Larkin, James, FRCP
Published in The lancet oncology (01.09.2016)
Published in The lancet oncology (01.09.2016)
Get full text
Journal Article
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Ascierto, Paolo A, Dr, Del Vecchio, Michele, MD, Robert, Caroline, Prof, Mackiewicz, Andrzej, Prof, Chiarion-Sileni, Vanna, MD, Arance, Ana, MD, Lebbé, Céleste, Prof, Bastholt, Lars, MD, Hamid, Omid, MD, Rutkowski, Piotr, Prof, McNeil, Catriona, MD, Garbe, Claus, Prof, Loquai, Carmen, MD, Dreno, Brigitte, Prof, Thomas, Luc, Prof, Grob, Jean-Jacques, Prof, Liszkay, Gabriella, Prof, Nyakas, Marta, MD, Gutzmer, Ralf, Prof, Pikiel, Joanna, MD, Grange, Florent, MD, Hoeller, Christoph, MD, Ferraresi, Virginia, MD, Smylie, Michael, MD, Schadendorf, Dirk, Prof, Mortier, Laurent, Prof, Svane, Inge Marie, MD, Hennicken, Delphine, MSc, Qureshi, Anila, MD, Maio, Michele, MD
Published in The lancet oncology (01.05.2017)
Published in The lancet oncology (01.05.2017)
Get full text
Journal Article
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
McArthur, Grant A, Prof, Chapman, Paul B, Prof, Robert, Caroline, MD, Larkin, James, MD, Haanen, John B, MD, Dummer, Reinhard, Prof, Ribas, Antoni, Prof, Hogg, David, Prof, Hamid, Omid, MD, Ascierto, Paolo A, MD, Garbe, Claus, Prof, Testori, Alessandro, MD, Maio, Michele, MD, Lorigan, Paul, MD, Lebbé, Celeste, Prof, Jouary, Thomas, MD, Schadendorf, Dirk, Prof, O'Day, Stephen J, MD, Kirkwood, John M., Prof, Eggermont, Alexander M, Prof, Dréno, Brigitte, Prof, Sosman, Jeffrey A, Prof, Flaherty, Keith T, MD, Yin, Ming, PhD, Caro, Ivor, MD, Cheng, Suzanne, PhD, Trunzer, Kerstin, PhD, Hauschild, Axel, Prof
Published in The lancet oncology (01.03.2014)
Published in The lancet oncology (01.03.2014)
Get full text
Journal Article